stockrowRapid Micro Biosystems, Inc.
RPID Healthcare Medical Devices
Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- 0.00%
- Free cash flow
- −24.0%
Quarter to June 2026, against a year earlier
Follow RPID
Alert me
Rapid Micro Biosystems, Inc. (RPID) EV/Sales
As of 5 November 2026, Rapid Micro Biosystems, Inc. (RPID) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −3.4× (March 2022) to 25.3× (November 2021); the current reading is higher than 54% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | — |
| FY2024 | −0.2× | — |
| FY2023 | −2.1× | — |
| FY2022 | −2.9× | — |
| FY2021 | 0.7× | — |
| FY2020 | −2.8× | — |
| FY2019 | −2.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.4× | (18.24%) |
| Mar 2026 | 2.9× | (12.01%) |
| Dec 2025 | 3.3× | (21.61%) |
| Sep 2025 | 4.2× | (1.96%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNOX Nano-X Imaging Ltd. compare | −0.5× |
| NSYS Nortech Systems Incorporated compare | 0.2× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| CVRX CVRx, Inc. compare | 0.7× |
| RPID Rapid Micro Biosystems, Inc. | 0.8× |
| TELA TELA Bio, Inc. compare | 1.0× |
| QTI QT Imaging Holdings, Inc. compare | 1.3× |
| NSPR InspireMD, Inc. compare | 2.5× |
| ELUT Elutia Inc. compare | 3.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)